225 related articles for article (PubMed ID: 28799444)
1. The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
LaRocca NG; Hudson LD; Rudick R; Amtmann D; Balcer L; Benedict R; Bermel R; Chang I; Chiaravalloti ND; Chin P; Cohen JA; Cutter GR; Davis MD; DeLuca J; Feys P; Francis G; Goldman MD; Hartley E; Kapoor R; Lublin F; Lundstrom G; Matthews PM; Mayo N; Meibach R; Miller DM; Motl RW; Mowry EM; Naismith R; Neville J; Panagoulias J; Panzara M; Phillips G; Robbins A; Sidovar MF; Smith KE; Sperling B; Uitdehaag BM; Weaver J;
Mult Scler; 2018 Oct; 24(11):1469-1484. PubMed ID: 28799444
[TBL] [Abstract][Full Text] [Related]
2. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
Feys P; Lamers I; Francis G; Benedict R; Phillips G; LaRocca N; Hudson LD; Rudick R;
Mult Scler; 2017 Apr; 23(5):711-720. PubMed ID: 28206826
[TBL] [Abstract][Full Text] [Related]
3. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
Motl RW; Cohen JA; Benedict R; Phillips G; LaRocca N; Hudson LD; Rudick R;
Mult Scler; 2017 Apr; 23(5):704-710. PubMed ID: 28206828
[TBL] [Abstract][Full Text] [Related]
4. Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.
Rudick RA; Larocca N; Hudson LD;
Mult Scler; 2014 Jan; 20(1):12-7. PubMed ID: 24057430
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of disability outcomes among young people with MS.
Ow N; Kuspinar A; Mayo NE;
Mult Scler Relat Disord; 2021 Jul; 52():102966. PubMed ID: 33934012
[TBL] [Abstract][Full Text] [Related]
6. Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.
Nolan RC; Akhand O; Rizzo JR; Galetta SL; Balcer LJ
J Neuroophthalmol; 2018 Jun; 38(2):202-209. PubMed ID: 29750734
[TBL] [Abstract][Full Text] [Related]
7. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
Balcer LJ; Raynowska J; Nolan R; Galetta SL; Kapoor R; Benedict R; Phillips G; LaRocca N; Hudson L; Rudick R;
Mult Scler; 2017 Apr; 23(5):734-747. PubMed ID: 28206829
[TBL] [Abstract][Full Text] [Related]
8. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
Benedict RH; DeLuca J; Phillips G; LaRocca N; Hudson LD; Rudick R;
Mult Scler; 2017 Apr; 23(5):721-733. PubMed ID: 28206827
[TBL] [Abstract][Full Text] [Related]
9. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
Strober L; DeLuca J; Benedict RH; Jacobs A; Cohen JA; Chiaravalloti N; Hudson LD; Rudick RA; LaRocca NG;
Mult Scler; 2019 Nov; 25(13):1781-1790. PubMed ID: 30334474
[TBL] [Abstract][Full Text] [Related]
10. Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis.
Uitdehaag BMJ
CNS Drugs; 2018 Jun; 32(6):543-558. PubMed ID: 29926371
[TBL] [Abstract][Full Text] [Related]
11. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.
Fischer JS; Rudick RA; Cutter GR; Reingold SC
Mult Scler; 1999 Aug; 5(4):244-50. PubMed ID: 10467383
[TBL] [Abstract][Full Text] [Related]
12. Disability as an outcome in MS clinical trials.
Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.
Ontaneda D; LaRocca N; Coetzee T; Rudick R;
Mult Scler; 2012 Aug; 18(8):1074-80. PubMed ID: 22740488
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome measures for research in multiple sclerosis.
Balcer LJ
J Neuroophthalmol; 2001 Dec; 21(4):296-301. PubMed ID: 11756863
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome measures in multiple sclerosis: A review.
Inojosa H; Schriefer D; Ziemssen T
Autoimmun Rev; 2020 May; 19(5):102512. PubMed ID: 32173519
[TBL] [Abstract][Full Text] [Related]
17. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
18. The effect of exercise training in adults with multiple sclerosis with severe mobility disability: A systematic review and future research directions.
Edwards T; Pilutti LA
Mult Scler Relat Disord; 2017 Aug; 16():31-39. PubMed ID: 28755682
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome measures in multiple sclerosis.
Uitdehaag BM
Handb Clin Neurol; 2014; 122():393-404. PubMed ID: 24507527
[TBL] [Abstract][Full Text] [Related]
20. Flexible modeling of disease activity measures improved prognosis of disability progression in relapsing-remitting multiple sclerosis.
Le Teuff G; Abrahamowicz M; Wynant W; Binquet C; Moreau T; Quantin C
J Clin Epidemiol; 2015 Mar; 68(3):307-16. PubMed ID: 25541382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
